Table Info

Table 1.

Examples of FDA-approved commercial tests for clinical application of ctDNA liquid biopsy

Test	Manufacturer	Cancer type indications	Biomarker (single cancer indication, pan-cancer/multi-cancer indications)	Technology
Therascreen^®, PIK3CA RGQ PCR Kit	Qiagen Manchester, Ltd.	Companion diagnostic Breast cancer: piqray (alpelisib)	PIK3CA	PCR
Cobas EGFR mutation Test v2	Roche Molecular Systems, Inc.	Companion diagnostic NSCLC: tarceva (erlotinib), tagrisso (osimertinib), iressa (gefitinib)	EGFR	PCR
Epi ProColon^®	Epigenomics AG	Ancillary screening: colorectal cancer	SEPT9 methylation	Bisulfite converted DNA and PCR
Guardant360^® CDx	Guardant Health, Inc.	Companion diagnostic NSCLC: tagrisso (osimertinib), rybrevant (amivantamab-vmjw), lumakras (sotorasib)	EGFR	NGS
FoundationOne^® Liquid CDx	Guardant Health, Inc.	Tumor mutation profiling: any solid tumor	73 genes
FoundationOne^® Liquid CDx	Foundation Medicine, Inc.	Companion diagnostic NSCLC: iressa (gefitinib), tagrisso (osimertinib), tarceva (erlotinib), alecensa (alectinib), tabrecta (capmatinib) Metastatic castrate resistant prostate cancer (mCRPC): rubraca (rucaparib), lynparza (olaparib) Ovarian cancer: rubraca (rucaparib) Breast cancer: piqray (alpelisib)	EGFR, ALK BRCA1/2, ATM BRCA1/2, PIK3CA	NGS
FoundationOne^® Liquid CDx	Foundation Medicine, Inc.	Tumor mutation profiling: any solid tumor	324 genes
BRAC Analysis CDx	Myriad Genetic Laboratories, Inc.	Companion diagnostic Breast cancer: lynparza (olaparib), talzenna (talazoparib) Ovarian cancer: lynparza (olaparib), rubraca (rucaparib) Pancreatic cancer: lynparza (olaparib) mCRPC: lynparza (olaparib)	BRCA	PCR

The table illustrates the characteristics of some FDA-approved commercial tests as companion diagnostic tests and as ancillary screening tests for the ctDNA liquid biopsy. PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; RGQ: rotor-gene Q; EGFR: epidermal growth factor receptor; SEPT9: septin 9; ALK: anaplastic lymphoma kinase; BRCA: breast cancer susceptibility genes; ATM: ataxia- telangiectasia mutated

Declarations

Author contributions

CMDC, GM: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing—review & editing. VC, FC, TT, SN: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Project administration, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Watanabe K, Nakamura Y, Low SK. Clinical implementation and current advancement of blood liquid biopsy in cancer. J Hum Genet. 2021;66:909–26. [DOI] [PubMed]

Borad MJ, LoRusso PM. Twenty-first century precision medicine in oncology: genomic profiling in patients with cancer. Mayo Clin Proc. 2017;92:1583–91. [DOI] [PubMed]

Savonarola A, Palmirotta R, Guadagni F, Silvestris F. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J. 2012;12:277–86. [DOI] [PubMed]

Rodríguez J, Avila J, Rolfo C, Ruíz-Patiño A, Russo A, Ricaurte L, et al. When tissue is an issue the liquid biopsy is nonissue: a review. Oncol Ther. 2021;9:89–110. [DOI] [PubMed] [PMC]

Liquid biopsy [Internet]. Bethesda: National Cancer Institute; [cited 2022 Mar 16]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy

Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11:858–73. [DOI] [PubMed]

Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust. 1869;14:146–9.

Mandel P, Métais P. Nuclear acids in human blood plasma. C R Seances Soc Biol Fil. 1948;142:241–3. French. [PubMed]

Wu K, Xing F, Wu SY, Watabe K. Extracellular vesicles as emerging targets in cancer: recent development from bench to bedside. Biochim Biophys Acta Rev Cancer. 2017;1868:538–63. [DOI] [PubMed] [PMC]

10.

Abouali H, Hosseini SA, Purcell E, Nagrath S, Poudineh M. Recent advances in device engineering and computational analysis for characterization of cell-released cancer biomarkers. Cancers (Basel). 2022;14:288. [DOI] [PubMed] [PMC]

11.

The cancer genome atlas [Internet]. Bethesda: National Human Genome Research Institute; [cited 2022 Apr 10]. Available from: https://www.genome.gov/Funded-Programs-Projects/Cancer-Genome-Atlas

12.

Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398–406. [DOI] [PubMed]

13.

Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem. 2011;57:1169–77. [DOI] [PubMed]

14.

Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57:1242–55. [DOI] [PubMed]

15.

Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–8. [DOI] [PubMed]

16.

Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, et al.; BioCAST/IFCT-1002 investigators. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res. 2014;20:4613–24. [DOI] [PubMed]

17.

Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 2014;5:3591. [DOI] [PubMed] [PMC]

18.

Komatsu S, Ichikawa D, Takeshita H, Morimura R, Hirajima S, Tsujiura M, et al. Circulating miR-18a: a sensitive cancer screening biomarker in human cancer. In Vivo. 2014;28:293–7. [PubMed]

19.

Zhou H, Zhu L, Song J, Wang G, Li P, Li W, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022;21:86. [DOI] [PubMed] [PMC]

20.

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–50. [PubMed]

21.

Prince AM, Adams WR. Virus-like particles in human plasma and serum: role of platelet lysosomes. J Natl Cancer Inst. 1966;37:153–66. [DOI]

22.

Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, et al. Detection of RAS gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res. 1993;53:2472–4. [PubMed]

23.

Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996;2:1035–7. [DOI] [PubMed]

24.

Pachmann K, Heiss P, Demel U, Tilz G. Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC^®). Clin Chem Lab Med. 2001;39:811–7. [DOI] [PubMed]

25.

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524–9. [DOI] [PubMed] [PMC]

26.

Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18:1177–85. [DOI] [PubMed]

27.

Isobe K, Hata Y, Kobayashi K, Hirota N, Sato K, Sano G, et al. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res. 2012;32:3339–44. [PubMed]

28.

Figg WD 2nd, Reid J. Monitor tumor burden with circulating tumor DNA. Cancer Biol Ther. 2013;14:697–8. [DOI] [PubMed] [PMC]

29.

Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 2014;134:1207–13. [DOI] [PubMed]

30.

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7:1034–47. [DOI] [PubMed] [PMC]

31.

New technologies offer the possibility of identifying cancer from a single blood draw [Internet]. Alexandria: American Society of Clinical Oncology and Association for Clinical Oncology; [cited 2019 Oct 10]. Available from: https://www.asco.org/about-asco/press-center/news-releases/new-technologies-offer-possibility-identifying-cancer-single

32.

FDA grants two new breakthrough device designations for Natera’s Signatera^TM MRD test [Internet]. Austin: Natera; [cited 2021 Mar 24]. Available from: https://www.natera.com/company/news/fda-grants-two-new-breakthrough-device-designations-for-nateras-signatera-mrd-test-2/

33.

Maas SLN, Breakefield XO, Weaver AM. Extracellular vesicles: unique intercellular delivery vehicles. Trends Cell Biol. 2017;27:172–88. [DOI] [PubMed] [PMC]

34.

Ding Y, Li W, Wang K, Xu C, Hao M, Ding L. Perspectives of the application of liquid biopsy in colorectal cancer. Biomed Res Int. 2020;2020:6843180. [DOI] [PubMed] [PMC]

35.

Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977. [DOI] [PubMed] [PMC]

36.

Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs — an update. Nat Rev Clin Oncol. 2018;15:541–63. [DOI] [PubMed]

37.

Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86. [DOI] [PubMed] [PMC]

38.

Best MG, Sol N, In’ t Veld SGJG, Vancura A, Muller M, Niemeijer AN, et al. Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell. 2017;32:238–52.E9. [DOI] [PubMed] [PMC]

39.

Joosse SA, Pantel K. Tumor-educated platelets as liquid biopsy in cancer patients. Cancer Cell. 2015;28:552–4. [DOI] [PubMed]

40.

Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci. 2014;51:160–71. [DOI] [PubMed]

41.

Danova M, Comolli G, Manzoni M, Torchio M, Mazzini G. Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: a critical evaluation (review). Mol Clin Oncol. 2016;4:909–17. [DOI] [PubMed] [PMC]

42.

Hofman P, Heeke S, Alix-Panabières C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol. 2019;30:1448–59. [DOI] [PubMed]

43.

Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res. 2020;39:95. Erratum in: J Exp Clin Cancer Res. 2020;39:120. [DOI] [PubMed] [PMC]

44.

Batista R, Vinagre N, Meireles S, Vinagre J, Prazeres H, Leão R, et al. Biomarkers for bladder cancer diagnosis and surveillance: a comprehensive review. Diagnostics (Basel). 2020;10:39. [DOI] [PubMed] [PMC]

45.

De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. [DOI] [PubMed] [PMC]

46.

Lee JS, Hur JY, Kim IA, Kim HJ, Choi CM, Lee JC, et al. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA. BMC Cancer. 2018;18:1236. [DOI] [PubMed] [PMC]

47.

Robertson DJ, Imperiale TF. Stool testing for colorectal cancer screening. Gastroenterology. 2015;149:1286–93. [DOI] [PubMed]

48.

Halvaei S, Daryani S, Eslami-S Z, Samadi T, Jafarbeik-Iravani N, Bakhshayesh TO, et al. Exosomes in cancer liquid biopsy: a focus on breast cancer. Mol Ther Nucleic Acids. 2018;10:131–41. [DOI] [PubMed] [PMC]

49.

Villatoro S, Mayo-de-Las-Casas C, Jordana-Ariza N, Viteri-Ramírez S, Garzón-Ibañez M, Moya-Horno I, et al. Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. Mol Oncol. 2019;13:2633–45. [DOI] [PubMed] [PMC]

50.

Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10:8152–62. [DOI] [PubMed]

51.

Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology. Genes Dev. 2017;31:1827–40. [DOI] [PubMed] [PMC]

52.

Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012;10:138. [DOI] [PubMed] [PMC]

53.

Domínguez-Vigil IG, Moreno-Martínez AK, Wang JY, Roehrl MHA, Barrera-Saldaña HA. The dawn of the liquid biopsy in the fight against cancer. Oncotarget. 2017;9:2912–22. [DOI] [PubMed] [PMC]

54.

Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14:623–31. [DOI] [PubMed]

55.

Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479–91. [DOI] [PubMed]

56.

Li N, Zuo H, Chen L, Liu H, Zhou J, Yao Y, et al. Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα. Cancer Manag Res. 2019;11:10939–48. [DOI] [PubMed] [PMC]

57.

Hu X, Zang X, Lv Y. Detection of circulating tumor cells: advances and critical concerns (review). Oncol Lett. 2021;21:422. [DOI] [PubMed] [PMC]

58.

Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease — latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409–24. [DOI] [PubMed]

59.

Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015;75:892–901. [DOI] [PubMed]

60.

Koch C, Kuske A, Joosse SA, Yigit G, Sflomos G, Thaler S, et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med. 2020;12:e11908. [DOI] [PubMed] [PMC]

61.

Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345:216–20. [DOI] [PubMed] [PMC]

62.

Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539–44. [DOI] [PubMed]

63.

Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20:897–903. [DOI] [PubMed]

64.

Faugeroux V, Pailler E, Oulhen M, Deas O, Brulle-Soumare L, Hervieu C, et al. Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. Nat Commun. 2020;11:1884. [DOI] [PubMed] [PMC]

65.

Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007;7:471–9. [DOI] [PubMed]

66.

Ramirez JM, Fehm T, Orsini M, Cayrefourcq L, Maudelonde T, Pantel K, et al. Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin Chem. 2014;60:214–21. [DOI] [PubMed]

67.

Garrel R, Mazel M, Perriard F, Vinches M, Cayrefourcq L, Guigay J, et al. Circulating tumor cells as a prognostic factor in recurrent or metastatic head and neck squamous cell carcinoma: the CIRCUTEC prospective study. Clin Chem. 2019;65:1267–75. [DOI] [PubMed]

68.

Cayrefourcq L, De Roeck A, Garcia C, Stoebner PE, Fichel F, Garima F, et al. S100-EPISPOT: a new tool to detect viable circulating melanoma cells. Cells. 2019;8:755. [DOI] [PubMed] [PMC]

69.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91. [DOI] [PubMed]

70.

Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol. 2010;11:1–13. [DOI] [PubMed]

71.

Resel Folkersma L, Olivier Gómez C, San José Manso L, Veganzones de Castro S, Galante Romo I, Vidaurreta Lázaro M, et al. Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation. Arch Esp Urol. 2010;63:23–31. [DOI] [PubMed]

72.

Morgan TM. Liquid biopsy: where did it come from, what is it, and where is it going? Investig Clin Urol. 2019;60:139–41. [DOI] [PubMed] [PMC]

73.

Leroy S, Benzaquen J, Mazzetta A, Marchand-Adam S, Padovani B, Israel-Biet D, et al.; AIR Project Study Group. Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France. BMJ Open. 2017;7:e018884. [DOI] [PubMed] [PMC]

74.

Sumanasuriya S, Omlin A, Armstrong A, Attard G, Chi KN, Bevan CL, et al. Consensus statement on circulating biomarkers for advanced prostate cancer. Eur Urol Oncol. 2018;1:151–9. [DOI] [PubMed]

75.

Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, et al. Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? A study of the OVCAD consortium. Oncotarget. 2017;8:106415–28. [DOI] [PubMed] [PMC]

76.

Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016;35:1216–24. [DOI] [PubMed]

77.

Maillet D, Allioli N, Peron J, Plesa A, Decaussin-Petrucci M, Tartas S, et al. Improved androgen receptor splice variant 7 detection using a highly sensitive assay to predict resistance to abiraterone or enzalutamide in metastatic prostate cancer patients. Eur Urol Oncol. 2021;4:609–17. [DOI] [PubMed]

78.

Asante DB, Calapre L, Ziman M, Meniawy TM, Gray ES. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time? Cancer Lett. 2020;468:59–71. [DOI] [PubMed]

79.

Banys-Paluchowski M, Fehm T, Neubauer H, Paluchowski P, Krawczyk N, Meier-Stiegen F, et al. Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer. Arch Gynecol Obstet. 2020;301:1027–35. [DOI] [PubMed] [PMC]

80.

Vanharanta S, Massagué J. Origins of metastatic traits. Cancer Cell. 2013;24:410–21. [DOI] [PubMed] [PMC]

81.

Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17:302–17. [DOI] [PubMed]

82.

Senft D, Leiserson MDM, Ruppin E, Ronai ZA. Precision oncology: the road ahead. Trends Mol Med. 2017;23:874–98. [DOI] [PubMed] [PMC]

83.

Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19:553–67. [DOI] [PubMed]

84.

Barriere G, Fici P, Gallerani G, Fabbri F, Zoli W, Rigaud M. Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Ann Transl Med. 2014;2:109. [DOI] [PubMed] [PMC]

85.

Alvarez Cubero MJ, Lorente JA, Robles-Fernandez I, Rodriguez-Martinez A, Puche JL, Serrano MJ. Circulating tumor cells: markers and methodologies for enrichment and detection. Methods Mol Biol. 2017;1634:283–303. [DOI] [PubMed]

86.

Pantel K, Alix-Panabières C. Cell lines from circulating tumor cells. Oncoscience. 2015;2:815–6. [DOI] [PubMed] [PMC]

87.

Kolostova K, Spicka J, Matkowski R, Bobek V. Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers. Am J Transl Res. 2015;7:1203–13. [PubMed] [PMC]

88.

Kolostova K, Zhang Y, Hoffman RM, Bobek V. In vitro culture and characterization of human lung cancer circulating tumor cells isolated by size exclusion from an orthotopic nude-mouse model expressing fluorescent protein. J Fluoresc. 2014;24:1531–6. [DOI] [PubMed] [PMC]

89.

Maheswaran S, Haber DA. Ex vivo culture of CTCs: an emerging resource to guide cancer therapy. Cancer Res. 2015;75:2411–5. [DOI] [PubMed] [PMC]

90.

Brock G, Castellanos-Rizaldos E, Hu L, Coticchia C, Skog J. Liquid biopsy for cancer screening, patient stratification and monitoring. Transl Cancer Res. 2015;4:280–90. [DOI]

91.

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750. [DOI] [PubMed] [PMC]

92.

Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9. [DOI] [PubMed]

93.

Lin J, Li J, Huang B, Liu J, Chen X, Chen XM, et al. Exosomes: novel biomarkers for clinical diagnosis. ScientificWorldJournal. 2015;2015:657086. [DOI] [PubMed] [PMC]

94.

Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820:940–8. [DOI] [PubMed]

95.

Tamura T, Yoshioka Y, Sakamoto S, Ichikawa T, Ochiya T. Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer. Extracell Vesicles Circ Nucleic Acids. 2021;2:148–74. [DOI]

96.

Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation techniques. Theranostics. 2017;7:789–804. [DOI] [PubMed] [PMC]

97.

Zhou B, Xu K, Zheng X, Chen T, Wang J, Song Y, et al. Application of exosomes as liquid biopsy in clinical diagnosis. Signal Transduct Target Ther. 2020;5:144. [DOI] [PubMed] [PMC]

98.

Nordin JZ, Lee Y, Vader P, Mäger I, Johansson HJ, Heusermann W, et al. Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. Nanomedicine. 2015;11:879–83. [DOI] [PubMed]

99.

Gupta S, Rawat S, Arora V, Kottarath SK, Dinda AK, Vaishnav PK, et al. An improvised one-step sucrose cushion ultracentrifugation method for exosome isolation from culture supernatants of mesenchymal stem cells. Stem Cell Res Ther. 2018;9:180. [DOI] [PubMed] [PMC]

100.

Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, et al. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J Extracell Vesicles. 2014;3:24858. [DOI] [PubMed] [PMC]

101.

Coumans FAW, Brisson AR, Buzas EI, Dignat-George F, Drees EEE, El-Andaloussi S, et al. Methodological guidelines to study extracellular vesicles. Circ Res. 2017;120:1632–48. [DOI] [PubMed]

102.

Helwa I, Cai J, Drewry MD, Zimmerman A, Dinkins MB, Khaled ML, et al. A comparative study of serum exosome isolation using differential ultracentrifugation and three commercial reagents. PLoS One. 2017;12:e0170628. [DOI] [PubMed] [PMC]

103.

Liu J, Chen Y, Pei F, Zeng C, Yao Y, Liao W, et al. Extracellular vesicles in liquid biopsies: potential for disease diagnosis. Biomed Res Int. 2021;2021:6611244. [DOI] [PubMed] [PMC]

104.

Soekmadji C, Corcoran NM, Oleinikova I, Jovanovic L; Australian Prostate Cancer Collaboration BioResource; Ramm GA, Nelson CC, Jenster G, Russell PJ. Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. Prostate. 2017;77:1416–23. [DOI] [PubMed]

105.

Zhou E, Li Y, Wu F, Guo M, Xu J, Wang S, et al. Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. EBioMedicine. 2021;67:103365. [DOI] [PubMed] [PMC]

106.

Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32:466–77. [DOI] [PubMed] [PMC]

107.

Zhao Z, Fan J, Hsu YS, Lyon CJ, Ning B, Hu TY. Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application. Lab Chip. 2019;19:1114–40. [DOI] [PubMed] [PMC]

108.

Liu Q, Yu Z, Yuan S, Xie W, Li C, Hu Z, et al. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer. Oncotarget. 2017;8:13048–58. [DOI] [PubMed] [PMC]

109.

Sandfeld-Paulsen B, Aggerholm-Pedersen N, Bæk R, Jakobsen KR, Meldgaard P, Folkersen BH, et al. Exosomal proteins as prognostic biomarkers in non-small cell lung cancer. Mol Oncol. 2016;10:1595–602. [DOI] [PubMed] [PMC]

110.

Sandfeld-Paulsen B, Jakobsen KR, Bæk R, Folkersen BH, Rasmussen TR, Meldgaard P, et al. Exosomal proteins as diagnostic biomarkers in lung cancer. J Thorac Oncol. 2016;11:1701–10. [DOI] [PubMed]

111.

Xue X, Zhao Y, Wang X, Qin L, Hu R. Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. J Cell Biochem. 2019;120:135–42. [DOI] [PubMed]

112.

Lee YR, Kim G, Tak WY, Jang SY, Kweon YO, Park JG, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Cancer. 2019;144:1444–52. [DOI] [PubMed]

113.

Peng ZY, Gu RH, Yan B. Downregulation of exosome-encapsulated miR-548c-5p is associated with poor prognosis in colorectal cancer. J Cell Biochem. 2018;120:1457–63. [DOI] [PubMed]

114.

Foj L, Ferrer F, Serra M, Arévalo A, Gavagnach M, Giménez N, et al. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis. Prostate. 2017;77:573–83. [DOI] [PubMed]

115.

Hou Y, Yu Z, Tam NL, Huang S, Sun C, Wang R, et al. Exosome-related lncRNAs as predictors of HCC patient survival: a prognostic model. Am J Transl Res. 2018;10:1648–62. [PubMed] [PMC]

116.

Wang X, Zhong W, Bu J, Li Y, Li R, Nie R, et al. Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer. Mol Carcinog. 2019;58:674–85. [DOI] [PubMed]

117.

Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523:177–82. Erratum in: Nature. 2022;610:E15–7. [DOI] [PubMed]

118.

Lan F, Yue X, Xia T. Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma. Oncol Lett. 2020;19:1967–74. [DOI]

119.

Nam GH, Choi Y, Kim GB, Kim S, Kim SA, Kim IS. Emerging prospects of exosomes for cancer treatment: from conventional therapy to immunotherapy. Adv Mater. 2020;32:e2002440. [DOI] [PubMed]

120.

Bellavia D, Raimondo S, Calabrese G, Forte S, Cristaldi M, Patinella A, et al. Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth. Theranostics. 2017;7:1333–45. [DOI] [PubMed] [PMC]

121.

Srivastava A, Amreddy N, Babu A, Panneerselvam J, Mehta M, Muralidharan R, et al. Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep. 2016;6:38541. [DOI] [PubMed] [PMC]

122.

Geeurickx E, Lippens L, Rappu P, De Geest BG, De Wever O, Hendrix A. Recombinant extracellular vesicles as biological reference material for method development, data normalization and assessment of (pre-)analytical variables. Nat Protoc. 2021;16:603–33. [DOI] [PubMed]

123.

Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164:57–68. [DOI] [PubMed] [PMC]

124.

Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci. 2000;906:161–8. [DOI] [PubMed]

125.

Sterzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426–37. [DOI] [PubMed]

126.

García-Silva S, Gallardo M, Peinado H. DNA-loaded extracellular vesicles in liquid biopsy: tiny players with big potential? Front Cell Dev Biol. 2021;8:622579. [DOI] [PubMed] [PMC]

127.

Siravegna G, Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol. 2014;15:449. [DOI] [PubMed] [PMC]

128.

van der Pol Y, Mouliere F. Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA. Cancer Cell. 2019;36:350–68. [DOI] [PubMed]

129.

Jiang P, Lo YMD. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics. Trends Genet. 2016;32:360–71. [DOI] [PubMed]

130.

Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17:89–97. [DOI] [PubMed]

131.

Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003;63:3966–8. [PubMed]

132.

Krishnamurthy N, Spencer E, Torkamani A, Nicholson L. Liquid biopsies for cancer: coming to a patient near you. J Clin Med. 2017;6:3. [DOI] [PubMed] [PMC]

133.

Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010;38:6159–75. [DOI] [PubMed] [PMC]

134.

Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 2011;6:e23418. [DOI] [PubMed] [PMC]

135.

Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016;7:48832–41. [DOI] [PubMed] [PMC]

136.

Li J, Dittmar RL, Xia S, Zhang H, Du M, Huang CC, et al. Cell-free DNA copy number variations in plasma from colorectal cancer patients. Mol Oncol. 2017;11:1099–111. [DOI] [PubMed] [PMC]

137.

Soave A, Chun FK, Hillebrand T, Rink M, Weisbach L, Steinbach B, et al. Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget. 2017;8:56398–407. [DOI] [PubMed] [PMC]

138.

Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, et al. Cell-free DNA from ascites and pleural effusions: molecular insights into genomic aberrations and disease biology. Mol Cancer Ther. 2017;16:948–55. [DOI] [PubMed]

139.

Li Z, Guo X, Tang L, Peng L, Chen M, Luo X, et al. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing. Tumour Biol. 2016;37:13111–9. [DOI] [PubMed]

140.

Stewart CM, Kothari PD, Mouliere F, Mair R, Somnay S, Benayed R, et al. The value of cell-free DNA for molecular pathology. J Pathol. 2018;244:616–27. [DOI] [PubMed] [PMC]

141.

Bos MK, Nasserinejad K, Jansen MPHM, Angus L, Atmodimedjo PN, de Jonge E, et al. Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. Mol Oncol. 2021;15:57–66. Erratum in: Mol Oncol. 2021;15:2818–9. [DOI] [PubMed] [PMC]

142.

Lin C, Liu X, Zheng B, Ke R, Tzeng CM. Liquid biopsy, ctDNA diagnosis through NGS. Life (Basel). 2021;11:890. [DOI] [PubMed] [PMC]

143.

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, et al. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Ann Oncol. 2019;30:1088–95. [DOI] [PubMed]

144.

Hao TB, Shi W, Shen XJ, Qi J, Wu XH, Wu Y, et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014;111:1482–9. [DOI] [PubMed] [PMC]

145.

Cicchillitti L, Corrado G, De Angeli M, Mancini E, Baiocco E, Patrizi L, et al. Circulating cell-free DNA content as blood based biomarker in endometrial cancer. Oncotarget. 2017;8:115230–43. [DOI] [PubMed] [PMC]

146.

Vizza E, Corrado G, De Angeli M, Carosi M, Mancini E, Baiocco E, et al. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. J Exp Clin Cancer Res. 2018;37:16. Erratum in: J Exp Clin Cancer Res. 2018;37:35. [DOI] [PubMed] [PMC]

147.

Fernandez-Garcia D, Hills A, Page K, Hastings RK, Toghill B, Goddard KS, et al. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res. 2019;21:149. [DOI] [PubMed] [PMC]

148.

Soliman SE, Alhanafy AM, Habib MSE, Hagag M, Ibrahem RAL. Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer. Biochem Biophys Rep. 2018;15:45–51. [DOI] [PubMed] [PMC]

149.

Leng S, Zheng J, Jin Y, Zhang H, Zhu Y, Wu J, et al. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis. Clin Chim Acta. 2018;477:160–5. [DOI] [PubMed]

150.

Ai B, Liu H, Huang Y, Peng P. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget. 2016;7:44583–95. [DOI] [PubMed] [PMC]

151.

Hanna GJ, Supplee JG, Kuang Y, Mahmood U, Lau CJ, Haddad RI, et al. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. Ann Oncol. 2018;29:1980–6. [DOI] [PubMed]

152.

Wei T, Zhang Q, Li X, Su W, Li G, Ma T, et al. Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer. Mol Cancer Ther. 2019;18:196–203. [DOI] [PubMed]

153.

Jung K, Stephan C, Lewandowski M, Klotzek S, Jung M, Kristiansen G, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 2004;205:173–80. [DOI] [PubMed]

154.

Patsch K, Matasci N, Soundararajan A, Diaz P, Agus DB, Ruderman D, et al. Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA). BMC Res Notes. 2019;12:275. [DOI] [PubMed] [PMC]

155.

Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2018;88:1–9. [DOI] [PubMed] [PMC]

156.

Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4:650–61. [DOI] [PubMed] [PMC]

157.

Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019;13:34. [DOI] [PubMed] [PMC]

158.

Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61:112–23. [DOI] [PubMed]

159.

Ye P, Cai P, Xie J, Wei Y. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: a systematic review and meta-analysis. PLoS One. 2021;16:e0248775. [DOI] [PubMed] [PMC]

160.

Köhn L, Johansson M, Grankvist K, Nilsson J. Liquid biopsies in lung cancer-time to implement research technologies in routine care? Ann Transl Med. 2017;5:278. [DOI] [PubMed] [PMC]

161.

Sorber L, Zwaenepoel K, Deschoolmeester V, Van Schil PE, Van Meerbeeck J, Lardon F, et al. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer. 2017;107:100–7. [DOI] [PubMed]

162.

Olmedillas-López S, Olivera-Salazar R, García-Arranz M, García-Olmo D. Current and emerging applications of droplet digital PCR in oncology: an updated review. Mol Diagn Ther. 2022;26:61–87. [DOI] [PubMed]

163.

Pérez-Callejo D, Romero A, Provencio M, Torrente M. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res. 2016;5:45–65. [DOI] [PubMed] [PMC]

164.

Narayan A, Carriero NJ, Gettinger SN, Kluytenaar J, Kozak KR, Yock TI, et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 2012;72:3492–8. [DOI] [PubMed] [PMC]

165.

Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71–88. [DOI] [PubMed]

166.

Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100:8817–22. [DOI] [PubMed] [PMC]

167.

Paweletz CP, Sacher AG, Raymond CK, Alden RS, O’Connell A, Mach SL, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res. 2016;22:915–22. [DOI] [PubMed] [PMC]

168.

Malapelle U, Pisapia P, Rocco D, Smeraglio R, di Spirito M, Bellevicine C, et al. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Transl Lung Cancer Res. 2016;5:505–10. [DOI] [PubMed] [PMC]

169.

Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, et al. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica. 2016;101:830–8. [DOI] [PubMed] [PMC]

170.

Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24:1872–80. [DOI] [PubMed] [PMC]

171.

Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra68. [DOI] [PubMed]

172.

Gale D, Lawson ARJ, Howarth K, Madi M, Durham B, Smalley S, et al. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS One. 2018;13:e0194630. [DOI] [PubMed] [PMC]

173.

Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108:9530–5. [DOI] [PubMed] [PMC]

174.

Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548–54. [DOI] [PubMed] [PMC]

175.

Napoli GC, Chau CH, Figg WD. Single whole genome sequencing analysis blazes the trail for precision medicine. Cancer Biol Ther. 2022;23:134–5. [DOI] [PubMed] [PMC]

176.

Tailor TD, Rao X, Campa MJ, Wang J, Gregory SG, Patz EF Jr. Whole exome sequencing of cell-free DNA for early lung cancer: a pilot study to differentiate benign from malignant CT-detected pulmonary lesions. Front Oncol. 2019;9:317. [DOI] [PubMed] [PMC]

177.

Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, et al. Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach. Clin Chem. 2015;61:838–49. [DOI] [PubMed]

178.

Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, et al. mFast-SeqS as a monitoring and pre-screening tool for tumor-specific aneuploidy in plasma DNA. Adv Exp Med Biol. 2016;924:147–55. [DOI] [PubMed]

179.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. [DOI] [PubMed] [PMC]

180.

Haque IS, Elemento O. Challenges in using ctDNA to achieve early detection of cancer. BioRxiv 237578 [Preprint]. 2017 [cited 2017 Dec 21]. Available from: https://www.biorxiv.org/content/10.1101/237578v1 [DOI]

181.

Hasenleithner SO, Speicher MR. A clinician’s handbook for using ctDNA throughout the patient journey. Mol Cancer. 2022;21:81. [DOI] [PubMed] [PMC]

182.

List of cleared or approved companion diagnostic devices (in vitro and imaging tools) [Internet]. Credit to the U.S. Food and Drug Administration; [cited 2022 Apr 18]. Available from: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools

183.

Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J. Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer. 2011;74:1–6. [DOI] [PubMed]

184.

Al-Kateb H, Nguyen TT, Steger-May K, Pfeifer JD. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). Mol Oncol. 2015;9:1737–43. [DOI] [PubMed] [PMC]

185.

Vitiello PP, De Falco V, Giunta EF, Ciardiello D, Cardone C, Vitale P, et al. Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): a single institution experience. Cancers (Basel). 2019;11:1504. [DOI] [PubMed] [PMC]

186.

Napolitano S, Caputo V, Ventriglia A, Martini G, Della Corte CM, De Falco V, et al. Liquid biopsy at home: delivering precision medicine for patients with cancer during the COVID-19 pandemic. Oncologist. 2022;27:e633–41. [DOI] [PubMed] [PMC]

187.

Aldea M, Cerbone L, Bayle A, Parisi C, Sarkozy C, Vasseur D, et al. Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients. Ann Oncol. 2021;32:1642–5. [DOI] [PubMed]

188.

Campos CDM, Jackson JM, Witek MA, Soper SA. Molecular profiling of liquid biopsy samples for precision medicine. Cancer J. 2018;24:93–103. [DOI] [PubMed] [PMC]

189.

Finkle JD, Boulos H, Driessen TM, Lo C, Blidner RA, Hafez A, et al. Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA. NPJ Precis Oncol. 2021;5:63. [DOI] [PubMed] [PMC]

190.

Russo A, Incorvaia L, Del Re M, Malapelle U, Capoluongo E, Gristina V, et al. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. ESMO Open. 2021;6:100164. [DOI] [PubMed] [PMC]

191.

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;1:1–16. [DOI] [PubMed] [PMC]

192.

Deans ZC, Butler R, Cheetham M, Dequeker EMC, Fairley JA, Fenizia F, et al. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. Virchows Arch. 2019;474:681–9. [DOI] [PubMed] [PMC]

193.

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29:1895–902. [DOI] [PubMed] [PMC]

194.

Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. CA Cancer J Clin. 2021;71:176–90. [DOI] [PubMed]

195.

Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124:345–58. [DOI] [PubMed] [PMC]

196.

Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 2018;24:4437–43. [DOI] [PubMed]

197.

Pisapia P, Pepe F, Iaccarino A, Sgariglia R, Nacchio M, Russo G, et al. Liquid biopsy analysis in clinical practice: focus on lung cancer. J Mol Pathol. 2021;2:241–54. [DOI]

198.

Chan HT, Chin YM, Nakamura Y, Low SK. Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications. Cancers (Basel). 2020;12:2277. [DOI] [PubMed] [PMC]

199.

van de Haar J, Hoes L, Voest E. Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine. ESMO Open. 2019;4:e000516. [DOI] [PubMed] [PMC]

200.

Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25:4691–700. [DOI] [PubMed]

201.

Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5:173–80. [DOI] [PubMed] [PMC]

202.

Guerrera LP, Suarato G, Napolitano R, Perrone A, Caputo V, Ventriglia A, et al. Mixed neuroendocrine non-neuroendocrine neoplasms of the gastrointestinal tract: a case series. Healthcare (Basel). 2022;10:708. [DOI] [PubMed] [PMC]

203.

Caputo V, De Falco V, Ventriglia A, Famiglietti V, Martinelli E, Morgillo F, et al. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Ther Adv Med Oncol. 2022;14:17588359221096878. [DOI] [PubMed] [PMC]

204.

Sardo E, Napolitano S, Della Corte CM, Ciardiello D, Raucci A, Arrichiello G, et al. Multi-omic approaches in colorectal cancer beyond genomic data. J Pers Med. 2022;12:128. [DOI] [PubMed] [PMC]

205.

Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25:1415–21. Erratum in: Nat Med. 2019;25:1949. [DOI] [PubMed] [PMC]

206.

Lu C, Zhang YC, Chen ZH, Zhou Q, Wu YL. Applications of circulating tumor DNA in immune checkpoint inhibition: emerging roles and future perspectives. Front Oncol. 2022;12:836891. [DOI] [PubMed] [PMC]

207.

Markou A, Tzanikou E, Lianidou E. The potential of liquid biopsy in the management of cancer patients. Semin Cancer Biol. 2022;84:69–79. [DOI] [PubMed]

208.

Chakraborty S, Hosen MI, Ahmed M, Shekhar HU. Onco-multi-OMICS approach: a new frontier in cancer research. Biomed Res Int. 2018;2018:9836256. [DOI] [PubMed] [PMC]

209.

Ding SC, Lo YMD. Cell-free DNA fragmentomics in liquid biopsy. Diagnostics (Basel). 2022;12:978. [DOI] [PubMed] [PMC]

210.

Peng Y, Mei W, Ma K, Zeng C. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. Front Oncol. 2021;11:763790. [DOI] [PubMed] [PMC]

211.

De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 2019;40:172–86. [DOI] [PubMed]

212.

Ulz P, Heitzer E, Geigl JB, Speicher MR. Patient monitoring through liquid biopsies using circulating tumor DNA. Int J Cancer. 2017;141:887–96. [DOI] [PubMed]

213.

Pasini L, Ulivi P. Liquid biopsy for the detection of resistance mechanisms in NSCLC: comparison of different blood biomarkers. J Clin Med. 2019;8:998. [DOI] [PubMed] [PMC]

214.

Venesio T, Siravegna G, Bardelli A, Sapino A. Liquid biopsies for monitoring temporal genomic heterogeneity in breast and colon cancers. Pathobiology. 2018;85:146–54. [DOI] [PubMed]

215.

Angeles AK, Janke F, Bauer S, Christopoulos P, Riediger AL, Sültmann H. Liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free DNA in cancer. Cancers (Basel). 2021;13:5615. [DOI] [PubMed] [PMC]

216.

Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369:eabb9601. [DOI] [PubMed] [PMC]

217.

Vacante M, Ciuni R, Basile F, Biondi A. The liquid biopsy in the management of colorectal cancer: an overview. Biomedicines. 2020;8:308. [DOI] [PubMed] [PMC]

218.

Remon J, García-Campelo R, de Álava E, Vera R, Rodríguez-Peralto JL, Rodríguez-Lescure Á, et al. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020;22:823–34. Erratum in: Clin Transl Oncol. 2020;22:961–2. [DOI] [PubMed] [PMC]

219.

Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430–5. [DOI] [PubMed]

220.

Malapelle U, Mayo de-Las-Casas C, Rocco D, Garzon M, Pisapia P, Jordana-Ariza N, et al. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. Br J Cancer. 2017;116:802–10. [DOI] [PubMed] [PMC]

221.

Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2015;24:206–12. [DOI] [PubMed]

222.

Hao YX, Fu Q, Guo YY, Ye M, Zhao HX, Wang Q, et al. Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis. Onco Targets Ther. 2017;10:945–53. [DOI] [PubMed] [PMC]

223.

Xie W, Xie L, Song X. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: a meta-analysis. Cancer Med. 2019;8:1218–31. [DOI] [PubMed] [PMC]

224.

Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep. 2014;4:6269. [DOI] [PubMed] [PMC]

225.

Tang M, Deng Z, Li B, Peng Y, Song M, Liu J. Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis. Int J Biol Markers. 2017;32:e421–7. [DOI] [PubMed]

226.

Hedtke M, Pessoa Rejas R, Froelich MF, Ast V, Duda A, Mirbach L, et al. Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care. Mol Oncol. 2021;16:2042–56. [DOI] [PubMed] [PMC]

227.

Companion diagnostic test [Internet]. Bethesda: National Cancer Institute; [cited 2022 Apr 26]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/companion-diagnostic-test

228.

Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:1491–505. [DOI] [PubMed]

229.

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19:254–66. [DOI] [PubMed]

230.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol. 2018;13:1248–68. [DOI] [PubMed]

231.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142:321–46. [DOI] [PubMed]

232.

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al.; AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–40. [DOI] [PubMed] [PMC]

233.

Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373–86. [DOI] [PubMed]

234.

Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24:3097–107. [DOI] [PubMed]

235.

Papadimitrakopoulou VA, Wu YL, Han JY, Ahn MJ, Ramalingam SS, John T, et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 2018;29:viii741. [DOI]

236.

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725–37. [DOI] [PubMed] [PMC]

237.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4:1527–34. [DOI] [PubMed] [PMC]

238.

Yu HA, Schoenfeld AJ, Makhnin A, Kim R, Rizvi H, Tsui D, et al. Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial. JAMA Oncol. 2020;6:1048–54. [DOI] [PubMed] [PMC]

239.

Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, et al. Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA. JCO Precis Oncol. 2018;2018:1–14. [DOI] [PubMed] [PMC]

240.

Dagogo-Jack I, Rooney M, Nagy RJ, Lin JJ, Chin E, Ferris LA, et al. Molecular analysis of plasma from patients with ROS1-positive NSCLC. J Thorac Oncol. 2019;14:816–24. [DOI] [PubMed] [PMC]

241.

Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC. Clin Cancer Res. 2020;26:2615–25. [DOI] [PubMed]

242.

Madsen AT, Winther-Larsen A, McCulloch T, Meldgaard P, Sorensen BS. Genomic profiling of circulating tumor DNA predicts outcome and demonstrates tumor evolution in ALK-positive non-small cell lung cancer patients. Cancers (Basel). 2020;12:947. [DOI] [PubMed] [PMC]

243.

Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov. 2020;10:688–701. Erratum in: Cancer Discov. 2020;10:1078. [DOI] [PubMed] [PMC]

244.

Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10:54–71. [DOI] [PubMed] [PMC]

245.

Dueling KRAS^G12C inhibitors achieve responses. Cancer Discov. 2020;10:10. [DOI] [PubMed]

246.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. 2018;36:1631–41. [DOI] [PubMed]

247.

Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165–72. [DOI] [PubMed]

248.

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al.; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929–40. [DOI] [PubMed]

249.

Ciruelos EM, Loibl S, Mayer IA, Campone M, Rugo HS, Arnedos M, et al. Abstract PD2-06: clinical outcomes of alpelisib plus fulvestrant in hormone receptorpositive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: biomarker analysis from the SOLAR-1 study. Cancer Res. 2021;81:PD2–06. [DOI]

250.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer. Clin Cancer Res. 2017;23:5687–95. [DOI] [PubMed] [PMC]

251.

Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21:1296–308. [DOI] [PubMed]

252.

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020;1:382–93. [DOI] [PubMed] [PMC]

253.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801. Erratum in: Nat Med. 2015;21:827. [DOI] [PubMed] [PMC]

254.

Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25:3046–53. [DOI] [PubMed]

255.

Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–40. [DOI] [PubMed] [PMC]

256.

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6. [DOI] [PubMed] [PMC]

257.

Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28:1325–32. [DOI] [PubMed] [PMC]

258.

Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol. 2017;11:208–19. [DOI] [PubMed] [PMC]

259.

Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Fenocchio E, et al. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: the CHRONOS trial. JCO. 2021;39:3506. [DOI] [PubMed] [PMC]

260.

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39:273–84. [DOI] [PubMed] [PMC]

261.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46. Erratum in: Lancet Oncol. 2016;17:e420. [DOI] [PubMed]

262.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317:2392–401. [DOI] [PubMed] [PMC]

263.

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94. [DOI] [PubMed]

264.

Walens A, Lin J, Damrauer JS, McKinney B, Lupo R, Newcomb R, et al. Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence. Nat Commun. 2020;11:5017. [DOI] [PubMed] [PMC]

265.

Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72:372–401. [DOI] [PubMed]

266.

Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, et al. Biomarker-guided anti-EGFR rechallenge therapy in metastatic colorectal cancer. Cancers (Basel). 2021;13:1941. Erratum in: Cancers (Basel). 2022;14:3900. [DOI] [PubMed] [PMC]

267.

Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Morris VK, et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell. 2018;34:148–62. [DOI] [PubMed]

268.

Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Mazard T, Vilar E, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26:731–6. [DOI] [PubMed] [PMC]

269.

Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. 2018;8:1270–85. [DOI] [PubMed] [PMC]

270.

Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30:243–9. [DOI] [PubMed] [PMC]

271.

Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324. [DOI] [PubMed] [PMC]

272.

Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, et al. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 2015;25:486–95. [DOI] [PubMed]

273.

Haselmann V, Gebhardt C, Brechtel I, Duda A, Czerwinski C, Sucker A, et al. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy. Clin Chem. 2018;64:830–42. [DOI] [PubMed]

274.

FDA approves first-line immunotherapy for patients with MSI-H/dMMR metastatic colorectal cancer [Internet]. Credit to the U.S. Food and Drug Administration; [cited 2022 Apr 26]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer

275.

FDA approves first cancer treatment for any solid tumor with a specific genetic feature [Internet]. Credit to the U.S. Food and Drug Administration; [cited 2022 Jun 2]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature

276.

FDA approves pembrolizumab for adults and children with TMB-H solid tumors [Internet]. Credit to the U.S. Food and Drug Administration; [cited 2022 June 2]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors

277.

Kasi PM, Klempner SJ, Starr JS, Shergill A, Bucheit LA, Weipert C, et al. Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI). JCO. 2022;40:56. [DOI]

278.

Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for immunotherapy: current developments and challenges. Am Soc Clin Oncol Educ Book. 2016;35:e493–503. [DOI] [PubMed]

279.

Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol. 2019;5:696–702. [DOI] [PubMed] [PMC]

280.

Chauhan PS, Chen K, Babbra RK, Feng W, Pejovic N, Nallicheri A, et al. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: a cohort study. PLoS Med. 2021;18:e1003732. Erratum in: PLoS Med. 2021;18:e1003876. [DOI] [PubMed] [PMC]

281.

Hita-Millan J, Carracedo A, Fernandez-Rozadilla C. Liquid Biopsy biomarkers for immunotherapy in non-small cell lung carcinoma: lessons learned and the road ahead. J Pers Med. 2021;11:971. [DOI] [PubMed] [PMC]

282.

Kilgour E, Rothwell DG, Brady G, Dive C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell. 2020;37:485–95. [DOI] [PubMed]

283.

Mauri G, Vitiello PP, Sogari A, Crisafulli G, Sartore-Bianchi A, Marsoni S, et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br J Cancer. 2022;127:394–407. [DOI] [PubMed] [PMC]

284.

Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21:79. [DOI] [PubMed] [PMC]

285.

Cecchini MJ, Yi ES. Liquid biopsy is a valuable tool in the diagnosis and management of lung cancer. J Thorac Dis. 2020;12:7048–56. [DOI] [PubMed] [PMC]

286.

Bracht JWP, Mayo-de-Las-Casas C, Berenguer J, Karachaliou N, Rosell R. The present and future of liquid biopsies in non-small cell lung cancer: combining four biosources for diagnosis, prognosis, prediction, and disease monitoring. Curr Oncol Rep. 2018;20:70. Erratum in: Curr Oncol Rep. 2020;22:52. [DOI] [PubMed]

287.

Barták BK, Fodor T, Kalmár A, Nagy ZB, Zsigrai S, Szigeti KA, et al. A liquid biopsy-based approach for monitoring treatment response in post-operative colorectal cancer patients. Int J Mol Sci. 2022;23:3774. [DOI] [PubMed] [PMC]

288.

Nagasaka M, Uddin MH, Al-Hallak MN, Rahman S, Balasubramanian S, Sukari A, et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021;20:82. [DOI] [PubMed] [PMC]

289.

Fattore L, Ruggiero CF, Liguoro D, Castaldo V, Catizone A, Ciliberto G, et al. The promise of liquid biopsy to predict response to immunotherapy in metastatic melanoma. Front Oncol. 2021;11:645069. [DOI] [PubMed] [PMC]

290.

Osei-Bordom DC, Sachdeva G, Christou N. Liquid biopsy as a prognostic and theranostic tool for the management of pancreatic ductal adenocarcinoma. Front Med (Lausanne). 2022;8:788869. [DOI] [PubMed] [PMC]

291.

Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, et al. Liquid biopsy for prognosis and treatment in metastatic colorectal cancer: circulating tumor cells vs. circulating tumor DNA. Target Oncol. 2021;16:309–24. Erratum in: Target Oncol. 2021;16:413. [DOI] [PubMed] [PMC]

292.

Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8:364ra155. [DOI] [PubMed] [PMC]

293.

Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, et al. Plasma ctDNA response is an early marker of treatment effect in advanced NSCLC. JCO Precis Oncol. 2021;5:393–402. [DOI] [PubMed] [PMC]

294.

Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2021;9:e001504. [DOI] [PubMed] [PMC]

295.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res. 2019;25:6644–52. [DOI] [PubMed] [PMC]

296.

Shepherd FA, Papadimitrakopoulou V, Mok T, Wu YL, Han JY, Ahn MJ, et al. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial. JCO. 2018;36:9027. [DOI]

297.

Song Y, Hu C, Xie Z, Wu L, Zhu Z, Rao C, et al.; written on behalf of AME Lung Cancer Collaborative Group. Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Transl Lung Cancer Res. 2020;9:269–79. [DOI] [PubMed] [PMC]

298.

Wei J, Feng J, Weng Y, Xu Z, Jin Y, Wang P, et al. The prognostic value of ctDNA and bTMB on immune checkpoint inhibitors in human cancer. Front Oncol. 2021;11:706910. [DOI] [PubMed] [PMC]

299.

Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1:873–81. [DOI] [PubMed]

300.

Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10:1842–53. [DOI] [PubMed] [PMC]

301.

Guibert N, Mazieres J, Delaunay M, Casanova A, Farella M, Keller L, et al. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget. 2017;8:38056–60. [DOI] [PubMed] [PMC]

302.

Darrigues L, Pierga JY, Bernard-Tessier A, Bièche I, Silveira AB, Michel M, et al. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. Breast Cancer Res. 2021;23:31. [DOI] [PubMed] [PMC]

303.

Li S, Lai H, Liu J, Liu Y, Jin L, Li Y, et al. Circulating tumor DNA predicts the response and prognosis in patients with early breast cancer receiving neoadjuvant chemotherapy. JCO Precis Oncol. 2020;4:244–57. [DOI] [PubMed] [PMC]

304.

Del Re M, Vivaldi C, Rofi E, Vasile E, Miccoli M, Caparello C, et al. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci Rep. 2017;7:7931. [DOI] [PubMed] [PMC]

305.

Kruger S, Heinemann V, Ross C, Diehl F, Nagel D, Ormanns S, et al. Repeated ^mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol. 2018;29:2348–55. [DOI] [PubMed]

306.

Lim Y, Kim S, Kang JK, Kim HP, Jang H, Han H, et al. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. Sci Rep. 2021;11:16333. [DOI] [PubMed] [PMC]

307.

Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL Study). Clin Cancer Res. 2017;23:5416–25. [DOI] [PubMed]

308.

Salvianti F, Gelmini S, Mancini I, Pazzagli M, Pillozzi S, Giommoni E, et al. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. Br J Cancer. 2021;125:94–100. [DOI] [PubMed] [PMC]

309.

Gray E, Rizos H, Reid A, Suzanah B, Michelle P, Johnny L, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6:42008–18. [DOI] [PubMed] [PMC]

310.

Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297–312. [DOI] [PubMed]

311.

Minimal residual disease [Internet]. Credit to the U.S. Food and Drug Administration; [cited 2022 May 25]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/minimal-residual-disease

312.

Szczepański T, Orfão A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2:409–17. [DOI] [PubMed]

313.

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38. [DOI] [PubMed]

314.

Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021;11:2968–86. [DOI] [PubMed] [PMC]

315.

DiNardo CD, Korde LA, Yurgelun MB. A case-based approach to understanding complex genetic information in an evolving landscape. Am Soc Clin Oncol Educ Book. 2021;41:1–11. [DOI] [PubMed]

316.

Huang F, Yang Y, Chen X, Jiang H, Wang H, Shen M, et al. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer. Clin Biochem. 2021;92:46–53. [DOI] [PubMed]

317.

Chera BS, Kumar S, Beaty BT, Marron D, Jefferys S, Green R, et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res. 2019;25:4682–90. [DOI] [PubMed] [PMC]

318.

Rolfo C, Russo A. Liquid biopsy for early stage lung cancer moves ever closer. Nat Rev Clin Oncol. 2020;17:523–4. [DOI] [PubMed]

319.

Ulrich B, Pradines A, Mazières J, Guibert N. Detection of tumor recurrence via circulating tumor DNA profiling in patients with localized lung cancer: clinical considerations and challenges. Cancers (Basel). 2021;13:3759. [DOI] [PubMed] [PMC]

320.

Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, et al. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019;30:1580–90. [DOI] [PubMed]

321.

Naidoo M, Gibbs P, Tie J. ctDNA and adjuvant therapy for colorectal cancer: time to re-invent our treatment paradigm. Cancers (Basel). 2021;13:346. [DOI] [PubMed] [PMC]

322.

Coakley M, Garcia-Murillas I, Turner NC. Molecular residual disease and adjuvant trial design in solid tumors. Clin Cancer Res. 2019;25:6026–34. [DOI] [PubMed]

323.

Wills B, Gorse E, Lee V. Role of liquid biopsies in colorectal cancer. Curr Probl Cancer. 2018;42:593–600. [DOI] [PubMed]

324.

Chin RI, Chen K, Usmani A, Chua C, Harris PK, Binkley MS, et al. Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA). Mol Diagn Ther. 2019;23:311–31. [DOI] [PubMed] [PMC]

325.

Honoré N, Galot R, van Marcke C, Limaye N, Machiels JP. Liquid biopsy to detect minimal residual disease: methodology and impact. Cancers (Basel). 2021;13:5364. [DOI] [PubMed] [PMC]

326.

Larribère L, Martens UM. Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors. Cancers (Basel). 2021;13:5698. [DOI] [PubMed] [PMC]

327.

Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D, et al. Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors. JCO Precis Oncol. 2022;6:e2100181. Erratum in: JCO Precis Oncol. 2022;6:e2200193. [DOI] [PubMed] [PMC]

328.

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al.; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9. [DOI] [PubMed]

329.

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al.; ADAURA Investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–23. [DOI] [PubMed]

330.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al.; TRACERx consortiumPEACE consortium; Swanton C. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–51. Erratum in: Nature. 2018;554:264. [DOI] [PubMed] [PMC]

331.

Killock D. DYNAMIC insights into MRD responses early after resection of NSCLC. Nat Rev Clin Oncol. 2019;16:661. [DOI] [PubMed]

332.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7:1394–403. [DOI] [PubMed] [PMC]

333.

Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer. Nat Cancer. 2020;1:176–83. [DOI] [PubMed] [PMC]

334.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:302ra133. [DOI] [PMC]

335.

Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 2019;5:1473–8. Erratum in: JAMA Oncol. 2020;6:162. [DOI] [PubMed] [PMC]

336.

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595:432–7. [DOI] [PubMed]

337.

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90. [DOI] [PubMed] [PMC]

338.

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8:346ra92. [DOI] [PubMed] [PMC]

339.

Diehn M, Alizadeh AA, Adams HP, Lee JJ, Klassen S, Palma JF, et al. Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA). JCO. 2017;35:3591. [DOI]

340.

Schøler LV, Reinert T, Ørntoft MW, Kassentoft CG, Árnadóttir SS, Vang S, et al. Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res. 2017;23:5437–45. [DOI] [PubMed]

341.

Anandappa G, Starling N, Begum R, Bryant A, Sharma S, Renner D, et al. Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II–III colorectal cancer patients in a U.K. multicenter prospective study (TRACC). JCO. 2021;39:102. [DOI]

342.

Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell- free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5:1124–31. Erratum in: JAMA Oncol. 2019;5:1232. [DOI] [PubMed] [PMC]

343.

Tie J, Cohen J, Wang Y, Li L, Kinde I, Elsaleh H, et al. The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC). J Clin Oncol. 2017;35:3521. [DOI]

344.

Hirahata T, Ul Quraish R, Quraish AU, Ul Quraish S, Naz M, Razzaq MA. Liquid biopsy: a distinctive approach to the diagnosis and prognosis of cancer. Cancer Inform. 2022;21:11769351221076062. [DOI] [PubMed] [PMC]

345.

Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5:1710–7. Erratum in: JAMA Oncol. 2019;5:1811. [DOI] [PubMed] [PMC]

346.

Loupakis F, Sharma S, Derouazi M, Murgioni S, Biason P, Rizzato MD, et al. Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. JCO Precis Oncol. 2021;5:1166–77. [DOI] [PubMed] [PMC]

347.

Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580:245–51. [DOI] [PubMed] [PMC]

348.

Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 2018;36:543–53. [DOI] [PubMed] [PMC]

349.

Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res. 2016;22:567–74. [DOI] [PubMed]

350.

Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019;30:1804–12. [DOI] [PubMed]

351.

Crosby D. Delivering on the promise of early detection with liquid biopsies. Br J Cancer. 2022;126:313–5. [DOI] [PubMed] [PMC]

352.

Freitas C, Sousa C, Machado F, Serino M, Santos V, Cruz-Martins N, et al. The role of liquid biopsy in early diagnosis of lung cancer. Front Oncol. 2021;11:634316. [DOI] [PubMed] [PMC]

353.

Santarpia M, Liguori A, D’Aveni A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, et al. Liquid biopsy for lung cancer early detection. J Thorac Dis. 2018;10:S882–97. [DOI] [PubMed] [PMC]

354.

Cowling T, Loshak H. An overview of liquid biopsy for screening and early detection of cancer. In: CADTH issues in emerging health technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019;179:1–13. [PubMed]

355.

Zheng H, Wu X, Yin J, Wang S, Li Z, You C. Clinical applications of liquid biopsies for early lung cancer detection. Am J Cancer Res. 2019;9:2567–79. [PubMed] [PMC]

356.

Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020;1:276–90. [DOI] [PubMed]

357.

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–30. [DOI] [PubMed] [PMC]

358.

McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdigones N, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 2019;11:eaax7392. [DOI] [PubMed] [PMC]

359.

Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25:4255–63. [DOI] [PubMed]

360.

Jones RM, Devers KJ, Kuzel AJ, Woolf SH. Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. Am J Prev Med. 2010;38:508–16. [DOI] [PubMed] [PMC]

361.

Steele RJ, McDonald PJ, Digby J, Brownlee L, Strachan JA, Libby G, et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterol J. 2013;1:198–205. [DOI] [PubMed] [PMC]

362.

Lamb YN, Dhillon S. Epi proColon^® 2.0 CE: a blood-based screening test for colorectal cancer. Mol Diagn Ther. 2017;21:225–32. [DOI] [PubMed]

363.

Duffy MJ, Diamandis EP, Crown J. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon? Clin Chem Lab Med. 2021;59:1353–61. [DOI] [PubMed]

364.

Sugeeta SS, Sharma A, Ng K, Nayak A, Vasdev N. Biomarkers in bladder cancer surveillance. Front Surg. 2021;8:735868. [DOI] [PubMed] [PMC]

365.

Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. eLife 2018;7:e32143. Erratum in: eLife. 2018;7:e43237. [DOI] [PubMed] [PMC]

366.

Haselmann V, Hedtke M, Neumaier M. Liquid profiling for cancer patient stratification in precision medicine-current status and challenges for successful implementation in standard care. Diagnostics (Basel). 2022;12:748. [DOI] [PubMed] [PMC]

367.

García-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Br J Cancer. 2022;127:592–602. [DOI] [PubMed] [PMC]